Corvino Sergio, de Divitiis Oreste, Corazzelli Giuseppe, Berardinelli Jacopo, Iuliano Adriana, Di Domenico Chiara, Lanni Vittoria, Altieri Roberto, Strianese Diego, Elefante Andrea, Mariniello Giuseppe
Department of Neurosciences and Reproductive and Odontostomatological Sciences, Division of Neurosurgery, School of Medicine, University of Naples "Federico II", Via S. Pansini 5, 80131 Naples, Italy.
Neurosurgery Department, Santa Maria delle Grazie Hospital, ASL Napoli 2 Nord, 80078 Naples, Italy.
Cancers (Basel). 2025 Mar 22;17(7):1068. doi: 10.3390/cancers17071068.
Naso-ethmoidal schwannoma is a rare slow-growing tumor arising from the Schwann cells of the sinonasal tract. This study discusses the evolution of surgical approaches to naso-ethmoidal schwannomas with respect to tumor growth and recent advances in minimally invasive techniques. A comprehensive literature review on Embase online electronic database on benign naso-ethmoidal schwannoma was performed. Demographic, clinical, neuroradiological, pathological, and surgical factors were analyzed and discussed. Twenty-five cases met the inclusion criteria. No predilection for gender was evident. The mean age at diagnosis was 40.2 years old. Nasal obstruction was the most common presenting symptom (64%), followed by headache (60%), hypo-anosmia (24%), and visual impairment (24%). Skull base and orbital involvement were registered in 64% and 16% of cases, respectively. Surgery is the unique curative treatment, with the endoscopic endonasal approach which plays the leading role (44%). Gross total resection was possible in all cases and was associated with no recurrence. The perioperative complication rate was 32% and mainly consisted of cerebrospinal fluid leakage. The mean time for treatment was 21 months. All patients were alive at last follow up. Surgery is the only curative treatment for naso-ethmoidal schwannomas, with the main goal to relief clinical manifestations. The endoscopic endonasal route represents the master approach for lesions confined to the midline. Transcranial and transorbital approaches play a complementary role when large intracranial extension and orbital involvement occur, respectively.
鼻筛窦神经鞘瘤是一种罕见的生长缓慢的肿瘤,起源于鼻窦道的施万细胞。本研究讨论了鼻筛窦神经鞘瘤手术方法的演变,涉及肿瘤生长情况以及微创技术的最新进展。我们在Embase在线电子数据库上对良性鼻筛窦神经鞘瘤进行了全面的文献综述。对人口统计学、临床、神经放射学、病理学和手术因素进行了分析和讨论。25例符合纳入标准。未发现明显的性别偏好。诊断时的平均年龄为40.2岁。鼻塞是最常见的首发症状(64%),其次是头痛(60%)、嗅觉减退(24%)和视力障碍(24%)。分别有64%和16%的病例出现颅底和眼眶受累。手术是唯一的治愈性治疗方法,其中内镜鼻内入路起主导作用(44%)。所有病例均实现了全切除,且无复发。围手术期并发症发生率为32%,主要为脑脊液漏。平均治疗时间为21个月。最后一次随访时所有患者均存活。手术是鼻筛窦神经鞘瘤唯一的治愈性治疗方法,主要目标是缓解临床表现。内镜鼻内途径是局限于中线病变的主要治疗方法。当出现较大的颅内扩展和眼眶受累时,经颅和经眶入路分别起辅助作用。